Premium
Clinical correlations and prognosis based on hyaluronic acid serum levels in patients with progressive systemic sclerosis
Author(s) -
LEVKSQUE H.,
BAUDOT N.,
DELPECH B.,
VAYSSAIRAT M.,
GANCEL A.,
LAURET PH.,
COURTOIS H.
Publication year - 1991
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1991.tb00619.x
Subject(s) - progressive systemic sclerosis , medicine , hyaluronic acid , systemic therapy , systemic disease , scleroderma (fungus) , multiple sclerosis , dermatology , oncology , pathology , immunology , immunopathology , disease , cancer , anatomy , breast cancer , inoculation
Summary The serum levels of hyaluronic acid (sHA) were measured using an affinoimmunoenzymatic assay in patients with distal (n= 16) and proximal (n= 15) progressive systemic sclerosis (PSS) and in 31 controls, The severity of PSS was evaluated using a standardized organ‐involvement score. The mean sHA was significantly higher in the patients with PSS than in controls (mean ± SD: 80 ± 43.4μg/l vs. 42.3 ± 19.1 μg/l, P < 0.001). sHA was significantly higher in patients with proximal PSS than in patients with distal PSS (106.4±44.6 μg/l vs. 55.4±23.8 μg/l. P < 0.001). A positive correlation was found between sHA and the disease score (r= 0.67, P < 0.001). sHA was also correlated with lung diffusion capacity for carbon monoxide (r=0. 70. P < 0.001). but only in those patients who had abnormal lung function, and therefore presumably had lung PSS involvement. We suggest that sHA could be an indicator of the degree of systemic involvement in PSS. Its prognostic value and possible use in the follow up of patients with PSS remain to be clarified.